Comparing E quil patch versus traditional catheter insulin pump in type 2 diabetes using continuous glucose monitoring metrics and profiles
Journal of Diabetes · 2024-04 · 16 (4)
DOI: 10.1111/1753-0407.13536 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes, online erschienen am 10.04.2024. Verfasst von Yu-Jiao Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
It is not clear whether there are differences in glycemic control between the Equil patch and the MMT‐712 insulin pump. Our objective was to compare two types of insulin pumps in the treatment of type 2 diabetes mellitus (T2DM), using continuous glucose monitoring (CGM) metrics and profiles.
Methods
This was a randomized case‐crossover clinical trial. Participants were hospitalized and randomly allocated to two groups and underwent two types of insulin pump treatments (group A: Equil patch—Medtronic MMT‐712 insulin pump; group B: Medtronic MMT‐712—Equil patch insulin pump) separated by a 1‐day washout period. Glycemic control was achieved after 7–8 days of insulin pump therapy. Each patient received CGM for 5 consecutive days (from day 1 to day 5). On day 3 of CGM performance, the Equil patch insulin pump treatment was switched to Medtronic MMT‐712 insulin pump treatment at the same basal and bolus insulin doses or vice versa. CGM metrics and profiles including glycemic variability (GV), time in range (TIR, 3.9–10.0 mmol/L), time below range (TBR, 10.0 mmol/L), and postprandial glucose excursions, as well as incidence of hypoglycemia.
Results
Forty‐six T2DM patients completed the study. There was no significant difference in parameters of daily GV and postprandial glucose excursions between the Equil patch insulin pump treatment and the Medtronic insulin pump treatment. Similarly, there was no between‐treatment difference in TIR, TBR, and TAR, as well as the incidence of hypoglycemia. image Conclusion The Equil patch insulin pump was similar to the traditional MMT‐712 insulin pump in terms of glycemic control. Equil patch insulin pump is a reliable tool for glycemic management of diabetes mellitus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- Department of Endocrinology, Affiliated Hospital of Jiangnan University, Wuxi, China.
ORCID-Profile: Yu-Jiao Li, Zi-Yue Shao, Yun-Qing Zhu, Da-Shuang Chen, Jian Zhu
Förderung
- National Key Research and Development Program of China
- Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau
Zitieren
APA
Li, Y. J., Shao, Z. Y., Zhu, Y. Q., Chen, D. S., & Zhu, J. (2024). Comparing E quil patch versus traditional catheter insulin pump in type 2 diabetes using continuous glucose monitoring metrics and profiles. Journal of Diabetes, 16(4). https://doi.org/10.1111/1753-0407.13536
Vancouver
Li YJ, Shao ZY, Zhu YQ, Chen DS, Zhu J. Comparing E quil patch versus traditional catheter insulin pump in type 2 diabetes using continuous glucose monitoring metrics and profiles. Journal of Diabetes. 2024;16(4). doi:10.1111/1753-0407.13536
BibTeX
@article{Li2024,
author = {Li, Yu-Jiao and Shao, Zi-Yue and Zhu, Yun-Qing and Chen, Da-Shuang and Zhu, Jian},
title = {Comparing E quil patch versus traditional catheter insulin pump in type 2 diabetes using continuous glucose monitoring metrics and profiles},
journal = {Journal of Diabetes},
year = {2024},
volume = {16},
number = {4},
doi = {10.1111/1753-0407.13536}
}
EUVIMED